Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib.

Matsusaka S, Hanna DL, Ning Y, Yang D, Cao S, Berger MD, Miyamoto Y, Suenaga M, Dan S, Mashima T, Seimiya H, Zhang W, Lenz HJ.

Cancer Sci. 2020 Feb;111(2):441-450. doi: 10.1111/cas.14273. Epub 2020 Jan 27.

2.

Author Correction: A practical guide to intelligent image-activated cell sorting.

Isozaki A, Mikami H, Hiramatsu K, Sakuma S, Kasai Y, Iino T, Yamano T, Yasumoto A, Oguchi Y, Suzuki N, Shirasaki Y, Endo T, Ito T, Hiraki K, Yamada M, Matsusaka S, Hayakawa T, Fukuzawa H, Yatomi Y, Arai F, Di Carlo D, Nakagawa A, Hoshino Y, Hosokawa Y, Uemura S, Sugimura T, Ozeki Y, Nitta N, Goda K.

Nat Protoc. 2019 Nov;14(11):3273. doi: 10.1038/s41596-019-0252-5.

PMID:
31624371
3.

Label-free chemical imaging flow cytometry by high-speed multicolor stimulated Raman scattering.

Suzuki Y, Kobayashi K, Wakisaka Y, Deng D, Tanaka S, Huang CJ, Lei C, Sun CW, Liu H, Fujiwaki Y, Lee S, Isozaki A, Kasai Y, Hayakawa T, Sakuma S, Arai F, Koizumi K, Tezuka H, Inaba M, Hiraki K, Ito T, Hase M, Matsusaka S, Shiba K, Suga K, Nishikawa M, Jona M, Yatomi Y, Yalikun Y, Tanaka Y, Sugimura T, Nitta N, Goda K, Ozeki Y.

Proc Natl Acad Sci U S A. 2019 Aug 6;116(32):15842-15848. doi: 10.1073/pnas.1902322116. Epub 2019 Jul 19.

4.

A practical guide to intelligent image-activated cell sorting.

Isozaki A, Mikami H, Hiramatsu K, Sakuma S, Kasai Y, Iino T, Yamano T, Yasumoto A, Oguchi Y, Suzuki N, Shirasaki Y, Endo T, Ito T, Hiraki K, Yamada M, Matsusaka S, Hayakawa T, Fukuzawa H, Yatomi Y, Arai F, Di Carlo D, Nakagawa A, Hoshino Y, Hosokawa Y, Uemura S, Sugimura T, Ozeki Y, Nitta N, Goda K.

Nat Protoc. 2019 Aug;14(8):2370-2415. doi: 10.1038/s41596-019-0183-1. Epub 2019 Jul 5. Erratum in: Nat Protoc. 2019 Oct 17;:.

PMID:
31278398
5.

Clarification of fast metal sphere movement in glass.

Nishioka N, Hidai H, Matsusaka S, Chiba A, Morita N.

Opt Express. 2019 Jun 24;27(13):18988-19001. doi: 10.1364/OE.27.018988.

PMID:
31252833
6.

Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).

Kondo K, Matsusaka S, Ishihara S, Horie H, Uehara K, Oguchi M, Murafushi K, Ueno M, Mizunuma N, Shimbo T, Kato D, Okuda J, Hashiguchi Y, Nakazawa M, Sunami E, Kawai K, Yamashita H, Okada T, Ishikawa Y, Fujii M, Nakajima T.

Radiother Oncol. 2019 May;134:199-203. doi: 10.1016/j.radonc.2019.02.006. Epub 2019 Feb 26.

PMID:
31005216
7.

Intelligent Image-Activated Cell Sorting.

Nitta N, Sugimura T, Isozaki A, Mikami H, Hiraki K, Sakuma S, Iino T, Arai F, Endo T, Fujiwaki Y, Fukuzawa H, Hase M, Hayakawa T, Hiramatsu K, Hoshino Y, Inaba M, Ito T, Karakawa H, Kasai Y, Koizumi K, Lee S, Lei C, Li M, Maeno T, Matsusaka S, Murakami D, Nakagawa A, Oguchi Y, Oikawa M, Ota T, Shiba K, Shintaku H, Shirasaki Y, Suga K, Suzuki Y, Suzuki N, Tanaka Y, Tezuka H, Toyokawa C, Yalikun Y, Yamada M, Yamagishi M, Yamano T, Yasumoto A, Yatomi Y, Yazawa M, Di Carlo D, Hosokawa Y, Uemura S, Ozeki Y, Goda K.

Cell. 2018 Sep 20;175(1):266-276.e13. doi: 10.1016/j.cell.2018.08.028. Epub 2018 Aug 27.

8.

Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

Hanna DL, Loupakis F, Yang D, Cremolini C, Schirripa M, Li M, Matsusaka S, Berger MD, Miyamoto Y, Zhang W, Ning Y, Antoniotti C, Salvatore L, Moran M, Zeger G, Astrow SH, Falcone A, Lenz HJ.

Clin Colorectal Cancer. 2018 Sep;17(3):e471-e488. doi: 10.1016/j.clcc.2018.03.006. Epub 2018 Mar 14.

9.

Micro-hole drilling by tightly focused vector beams.

Matsusaka S, Kozawa Y, Sato S.

Opt Lett. 2018 Apr 1;43(7):1542-1545. doi: 10.1364/OL.43.001542.

PMID:
29601025
10.

A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer -ACTOR Study.

Suenaga M, Akiyoshi T, Shinozaki E, Fujimoto Y, Matsusaka S, Konishi T, Nagayama S, Fukunaga Y, Kawakami K, Yokokawa T, Sugisaki T, Ueno M, Yamaguchi T.

Anticancer Res. 2018 Mar;38(3):1741-1747.

PMID:
29491111
11.

Correction to: Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC‑06).

Kimura Y, Fujii M, Masuishi T, Nishikawa K, Kunisaki C, Matsusaka S, Segawa Y, Nakamura M, Sasaki K, Nagao N, Hatachi Y, Yuasa Y, Asami S, Takeuchi M, Furukawa H, Nakajima T; JACCRO GC-06 Study Group.

Gastric Cancer. 2018 May;21(3):428. doi: 10.1007/s10120-017-0784-8.

12.

A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.

Berger MD, Stintzing S, Heinemann V, Cao S, Yang D, Sunakawa Y, Matsusaka S, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Zhang W, Cremolini C, Falcone A, Loupakis F, Lenz HJ.

Clin Cancer Res. 2018 Feb 15;24(4):784-793. doi: 10.1158/1078-0432.CCR-17-1663. Epub 2017 Dec 5.

13.

Secondary central nervous system lymphoma surrounding a region injured by subarachnoid hemorrhage and subsequent aneurysmal clipping.

Murata Y, Hata Y, Noda Y, Matsusaka S, Fukui N, Kadota T, Iwata J, Machida T, Yamagami T.

Biomed Rep. 2017 Nov;7(5):474-476. doi: 10.3892/br.2017.981. Epub 2017 Sep 11.

14.

Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.

Berger MD, Stintzing S, Heinemann V, Yang D, Cao S, Sunakawa Y, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Soni S, Zhang W, Falcone A, Loupakis F, Lenz HJ.

Ann Oncol. 2017 Nov 1;28(11):2780-2785. doi: 10.1093/annonc/mdx412.

15.

Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06).

Kimura Y, Fujii M, Masuishi T, Nishikawa K, Kunisaki C, Matsusaka S, Segawa Y, Nakamura M, Sasaki K, Nagao N, Hatachi Y, Yuasa Y, Asami S, Takeuchi M, Furukawa H, Nakajima T; JACCRO GC-06 Study Group.

Gastric Cancer. 2018 May;21(3):421-427. doi: 10.1007/s10120-017-0766-x. Epub 2017 Sep 21. Erratum in: Gastric Cancer. 2017 Dec 12;:.

16.

Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.

Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T, Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ.

Int J Cancer. 2017 Sep 15;141(6):1222-1230. doi: 10.1002/ijc.30810. Epub 2017 Jun 21.

17.

Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.

Mishima Y, Matsusaka S, Chin K, Mikuniya M, Minowa S, Takayama T, Shibata H, Kuniyoshi R, Ogura M, Terui Y, Mizunuma N, Hatake K.

Target Oncol. 2017 Jun;12(3):341-351. doi: 10.1007/s11523-017-0493-6.

PMID:
28508152
18.

Prognostic impact of FOXF1 polymorphisms in gastric cancer patients.

Matsusaka S, Wu AH, Cao S, Hanna DL, Chin K, Yang D, Zhang W, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Stremitzer S, Yamauchi S, Okazaki S, Berger MD, Parekh A, Miyamoto Y, Mizunuma N, Lenz HJ.

Pharmacogenomics J. 2018 Apr;18(2):262-269. doi: 10.1038/tpj.2017.9. Epub 2017 Apr 11.

PMID:
28398355
19.

Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.

Berger MD, Yamauchi S, Cao S, Hanna DL, Sunakawa Y, Schirripa M, Matsusaka S, Yang D, Groshen S, Zhang W, Ning Y, Okazaki S, Miyamoto Y, Suenaga M, Lonardi S, Cremolini C, Falcone A, Heinemann V, Loupakis F, Stintzing S, Lenz HJ.

Eur J Cancer. 2017 May;77:13-20. doi: 10.1016/j.ejca.2017.02.020. Epub 2017 Mar 26.

PMID:
28347919
20.

Letter in response to "Our HER2 is same as yours".

Matsusaka S, Yoshida K.

Transl Gastroenterol Hepatol. 2016 Mar 16;1:18. doi: 10.21037/tgh.2016.03.01. eCollection 2016. No abstract available.

21.

Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients.

Hosoya K, Matsusaka S, Kashiwada T, Suzuki K, Ureshino N, Sato A, Miki Y, Kitera K, Hirai M, Hatake K, Kimura S, Sueoka-Aragane N.

Pathol Oncol Res. 2017 Oct;23(4):737-744. doi: 10.1007/s12253-016-0175-1. Epub 2017 Jan 5.

PMID:
28058585
22.

Experimental and theoretical study on the driving force and glass flow by laser-induced metal sphere migration in glass.

Hidai H, Wada J, Iwamoto T, Matsusaka S, Chiba A, Kishi T, Morita N.

Sci Rep. 2016 Dec 9;6:38545. doi: 10.1038/srep38545.

23.

Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection.

Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S, Parekh A, Okazaki S, Hanna D, Astrow SH, Moran M, Hernandez J, Stephens C, Scherer SJ, Stift J, Wrba F, Gruenberger T, Lenz HJ.

Mol Cancer Ther. 2016 Nov;15(11):2814-2821. Epub 2016 Aug 17.

24.

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.

Sebio A, Stintzing S, Heinemann V, Sunakawa Y, Zhang W, Ichikawa W, Tsuji A, Takahashi T, Parek A, Yang D, Cao S, Ning Y, Stremitzer S, Matsusaka S, Okazaki S, Barzi A, Berger MD, Lenz HJ.

Pharmacogenomics J. 2018 Jan;18(1):43-48. doi: 10.1038/tpj.2016.69. Epub 2016 Oct 4.

25.

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy.

Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Ueno M, Mizunuma N, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Parekh A, Okazaki S, Berger MD, El-Khoueiry R, Mendez A, Ichikawa W, Loupakis F, Lenz HJ.

Pharmacogenomics J. 2017 Dec;17(6):543-550. doi: 10.1038/tpj.2016.59. Epub 2016 Aug 9.

PMID:
27503580
26.

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012.

Berger MD, Yang D, Sunakawa Y, Zhang W, Ning Y, Matsusaka S, Okazaki S, Miyamoto Y, Suenaga M, Schirripa M, Lenz AM, Bohanes P, Barzi A, Figueiredo JC, Hanna DL, Lenz HJ.

Oncotarget. 2016 Aug 16;7(33):53668-53678. doi: 10.18632/oncotarget.10696.

27.

Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer.

Sunakawa Y, Cao S, Volz NB, Berger MD, Yang D, Parekh A, Zhang W, Matsusaka S, Ning Y, Stremitzer S, Stintzing S, Sebio A, Okazaki S, Wakatsuki T, Azuma M, Watanabe M, Koizumi W, Wu AH, Lenz HJ.

Pharmacogenomics J. 2017 Dec;17(6):528-534. doi: 10.1038/tpj.2016.46. Epub 2016 May 31.

PMID:
27241062
28.

Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.

Okazaki S, Loupakis F, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ.

Mol Cancer Ther. 2016 Jul;15(7):1740-5. doi: 10.1158/1535-7163.MCT-15-0931. Epub 2016 May 11.

29.

A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer.

Nakayama N, Ishido K, Chin K, Nishimura K, Azuma M, Matsusaka S, Inokuchi Y, Tanabe S, Kumekawa Y, Koizumi W.

Gastric Cancer. 2017 Mar;20(2):350-357. doi: 10.1007/s10120-016-0614-4. Epub 2016 May 17.

PMID:
27189323
30.

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.

Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T.

Oncotarget. 2016 Jun 7;7(23):34811-23. doi: 10.18632/oncotarget.9187.

31.

Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy.

Matsusaka S, Kobunai T, Yamamoto N, Chin K, Ogura M, Tanaka G, Matsuoka K, Ishikawa Y, Mizunuma N, Yamaguchi T.

Genes Cancer. 2016 Jan;7(1-2):27-35.

32.

RAS mutation is a prognostic biomarker in colorectal cancer patients with metastasectomy.

Osumi H, Shinozaki E, Suenaga M, Matsusaka S, Konishi T, Akiyoshi T, Fujimoto Y, Nagayama S, Fukunaga Y, Ueno M, Mise Y, Ishizawa T, Inoue Y, Takahashi Y, Saiura A, Uehara H, Mun M, Okumura S, Mizunuma N, Miki Y, Yamaguchi T.

Int J Cancer. 2016 Aug 15;139(4):803-11. doi: 10.1002/ijc.30106. Epub 2016 Apr 19.

33.

TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.

Matsusaka S, Zhang W, Cao S, Hanna DL, Sunakawa Y, Sebio A, Ueno M, Yang D, Ning Y, Parekh A, Okazaki S, Berger MD, Ichikawa W, Mizunuma N, Lenz HJ.

Mol Cancer Ther. 2016 Jun;15(6):1405-11. doi: 10.1158/1535-7163.MCT-15-0751. Epub 2016 Mar 16.

34.

Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.

Matsusaka S, Hanna DL, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Okazaki S, Berger MD, Miyamato Y, Parekh A, Stintzing S, Loupakis F, Lenz HJ.

Clin Cancer Res. 2016 Jul 1;22(13):3218-26. doi: 10.1158/1078-0432.CCR-15-2422. Epub 2016 Feb 2.

35.

Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients.

Osumi H, Matsusaka S, Wakatsuki T, Suenaga M, Shinozaki E, Mizunuma N.

Mol Clin Oncol. 2015 Nov;3(6):1295-1300. Epub 2015 Aug 31.

36.

Genetic variants associated with colorectal brain metastases susceptibility and survival.

Stremitzer S, Berghoff AS, Volz NB, Zhang W, Yang D, Stintzing S, Ning Y, Sunakawa Y, Yamauchi S, Sebio A, Matsusaka S, Okazaki S, Hanna D, Parekh A, Mendez A, Berger MD, El-Khoueiry R, Birner P, Preusser M, Lenz HJ.

Pharmacogenomics J. 2017 Jan;17(1):29-35. doi: 10.1038/tpj.2015.86. Epub 2015 Dec 22.

PMID:
26689941
37.

Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients.

Sato Y, Matsusaka S, Suenaga M, Shinozaki E, Mizunuma N.

Onco Targets Ther. 2015 Nov 11;8:3329-36. doi: 10.2147/OTT.S89241. eCollection 2015.

38.

Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.

Osumi H, Shinozaki E, Osako M, Kawazoe Y, Oba M, Misaka T, Goto T, Kamo H, Suenaga M, Kumekawa Y, Ogura M, Ozaka M, Matsusaka S, Chin K, Hatake K, Mizunuma N.

Mol Clin Oncol. 2015 Sep;3(5):1053-1057. Epub 2015 Jul 9.

39.

Erratum to: Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).

Matsusaka S, Nashimoto A, Nishikawa K, Miki A, Miwa H, Yamaguchi K, Yoshikawa T, Ochiai A, Morita S, Sano T, Kodera Y, Kakeji Y, Sakamoto J, Saji S, Yoshida K.

Gastric Cancer. 2016 Jul;19(3):1026. No abstract available.

40.

Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer.

Sunakawa Y, Cao S, Berger MD, Matsusaka S, Yang D, Zhang W, Ning Y, Parekh A, Stremitzer S, Mendez A, Okazaki S, Wakatsuki T, Azuma M, Shimada K, Watanabe M, Koizumi W, Wu AH, Lenz HJ.

Pharmacogenomics J. 2017 Jan;17(1):36-41. doi: 10.1038/tpj.2015.77. Epub 2015 Oct 27.

PMID:
26503819
41.

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?

Osumi H, Shinozaki E, Suenaga M, Kumekawa Y, Ogura M, Ozaka M, Matsusaka S, Chin K, Yamamoto N, Mizunuma N.

BMC Cancer. 2015 Oct 21;15:760. doi: 10.1186/s12885-015-1751-6.

42.

Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.

Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, Yang D, Zhang W, Ning Y, Stremitzer S, Matsusaka S, Yamauchi S, Parekh A, Okazaki S, Berger MD, Graver S, Mendez A, Scherer SJ, Loupakis F, Lenz HJ.

Ann Oncol. 2015 Dec;26(12):2450-6. doi: 10.1093/annonc/mdv474. Epub 2015 Sep 28.

43.

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.

Sebio A, Matsusaka S, Zhang W, Yang D, Ning Y, Stremitzer S, Stintzing S, Sunakawa Y, Yamauchi S, Fujimoto Y, Ueno M, Lenz HJ.

Pharmacogenomics J. 2016 Aug;16(4):312-9. doi: 10.1038/tpj.2015.64. Epub 2015 Sep 15.

44.

A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial).

Matsusaka S, Ishihara S, Kondo K, Horie H, Uehara K, Oguchi M, Murofushi K, Ueno M, Mizunuma N, Shimbo T, Kato D, Okuda J, Hashiguchi Y, Nakazawa M, Sunami E, Kawai K, Yamashita H, Okada T, Ishikawa Y, Nakajima T, Watanabe T.

Radiother Oncol. 2015 Aug;116(2):209-13. doi: 10.1016/j.radonc.2015.08.002. Epub 2015 Aug 31.

PMID:
26337743
45.

Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab.

Osumi H, Matsusaka S, Suenaga M, Shinozaki E, Mizunuma N.

Onco Targets Ther. 2015 Aug 6;8:2005-13. doi: 10.2147/OTT.S87101. eCollection 2015.

46.

Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).

Matsusaka S, Nashimoto A, Nishikawa K, Miki A, Miwa H, Yamaguchi K, Yoshikawa T, Ochiai A, Morita S, Sano T, Kodera Y, Kakeji Y, Sakamoto J, Saji S, Yoshida K.

Gastric Cancer. 2016 Jul;19(3):839-51. doi: 10.1007/s10120-015-0518-8. Epub 2015 Aug 12. Erratum in: Gastric Cancer. 2016 Jul;19(3):1026.

47.

Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer.

Osumi H, Yoshio T, Chin K, Ogura M, Kumekawa Y, Suenaga M, Matsusaka S, Shinozaki E, Miyamoto Y, Morishige K, Ishiyama A, Hirasawa T, Tsuchida T, Yamamoto Y, Fujisaki J, Igarashi M, Mizunuma N.

Gastric Cancer. 2016 Apr;19(2):625-630. doi: 10.1007/s10120-015-0517-9. Epub 2015 Aug 11.

PMID:
26260873
48.

Cytokeratin-20 and Survivin-Expressing Circulating Tumor Cells Predict Survival in Metastatic Colorectal Cancer Patients by a Combined Immunomagnetic qRT-PCR Approach.

Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ.

Mol Cancer Ther. 2015 Oct;14(10):2401-8. doi: 10.1158/1535-7163.MCT-15-0359. Epub 2015 Jul 30.

49.

Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.

Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A, Folwaczny M, Yang D, Ning Y, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S, Yamauchi S, Loupakis F, Cremolini C, Falcone A, Lenz HJ.

Mol Cancer Ther. 2015 Oct;14(10):2374-81. doi: 10.1158/1535-7163.MCT-15-0121. Epub 2015 Jul 23.

50.

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.

Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Yamaguchi T.

Drug Des Devel Ther. 2015 Jun 16;9:3099-108. doi: 10.2147/DDDT.S85567. eCollection 2015.

Supplemental Content

Loading ...
Support Center